Table 3. Association between RTK/RAS-related genes and clinical outcome.
| OS | PFS | ||||||
|---|---|---|---|---|---|---|---|
| N | Median, months (95%CI) | HR (95%CI)a | HR (95%CI)b | Median, (95%CI) | HR (95%CI)a | HR (95%CI)b | |
| KRAS | |||||||
| Wild type | 144 | 14.9 (12.3–18.3) | 1 (Reference) | 1 (Reference) | 7.3 (5.5–8.8) | 1 (Reference) | 1 (Reference) |
| Mutant type | 6 | 8.8 (2.0–10.9) | 10.97 (2.5–48.26) | 5.06 (1.96–13.08) | 3.1 (1.1–7.5) | 8.66 (1.81–41.4) | 5.93 (1.9–18.51) |
| p value | 0.005 | < 0.001 | 0.021 | 0.002 | |||
| MET | |||||||
| Non-amp | 138 | 14.9 (12.3–17.5) | 1 (Reference) | 1 (Reference) | 7.3 (5.7–8.8) | 1 (Reference) | 1 (Reference) |
| Amp | 6 | 7.0 (5.9–10.5) | 5.2 (1.40–19.27) | 4.81 (1.53–15.12) | 4.7 (0–20.5) | 1.55 (0.54–4.51) | 1.83(0.57–5.81) |
| p value | 0.033 | 0.007 | 0.59 | 0.3 | |||
Non-amp, non-amplification; Amp, amplification.
P value was based on log-rank test for PFS and OS in the univariate analysis (a) and Wald test for PFS and OS in the multivariable Cox regression model adjusting for age, Eastern Cooperative Oncology Group performance status, primary tumor site, number of metastatic sites, and liver involvement (b).